Year: 2010
Type: article
Abstract: Cetuximab, a recombinant chimeric monoclonal antibody, has been successfully used in the treatment of the head and neck and colorectal cancers. We present a review of its mechanism of action, indications, side effects and economic issues, accompanied by a clinical example from our institution.
DOI: 10.3174/ajnr.a2054
Authors: W. Bou-Assaly, S. Mukherji
Language: German
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
OpenAlex ID: W4253593059
